In patients with advanced NSCLC receiving anti-PD1/PD-L1 ICI, > 50% ctDNA mutant allele fraction decrease from baseline was associated with radiographic response and superior PFS and OS [70]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.